Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?

dc.contributor.authorNourie, Nicole
dc.contributor.authorNassereddine, Hussein
dc.contributor.authorMouawad, Sarah
dc.contributor.authorChebbou, Louaa
dc.contributor.authorGhaleb, Rita
dc.contributor.authorAbbas, Fatmeh Ibrahim
dc.contributor.authorAzar, Hiba
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:14Z
dc.date.available2025-01-24T12:10:14Z
dc.date.issued2022
dc.description.abstractBackground: Antibody-mediated rejection (AMR) was described in kidney transplant patients after viral infections, such as the cytomegalovirus. Very few cases were recently reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, probably in the context of lowering of immunosuppressive therapy. To date, no direct immunological link was proved to explain a connection between the coronavirus disease 19 (COVID-19) infection and antibody-mediated rejection (AMR) if it exists. Case presentation: Here we try to find this association by presenting the case of a low immunological risk patient who presented, six years post-transplant, with c4d negative antibody mediated rejection due to an anti-HLA-C17 de novo donor specific antibody (DSA) after contracting the coronavirus disease 19. The HLA-Cw17 activated the antibody-dependent cell-mediated cytotoxicity via the KIR2DS1 positive NK cells. Discussion and conclusions: This case report mayprove a direct role for COVID-19 infection in AMRs in the kidney transplantrecipients, leading us to closely monitor kidney transplant recipients,especially if they have “at-risk” donor antigens. © 2022, The Author(s).
dc.identifier.doihttps://doi.org/10.1186/s12882-022-02713-x
dc.identifier.eid2-s2.0-85125873294
dc.identifier.pmid35247969
dc.identifier.urihttp://hdl.handle.net/10938/32288
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.relation.ispartofBMC Nephrology
dc.sourceScopus
dc.subjectAntibody mediated rejection
dc.subjectCase report
dc.subjectCovid 19
dc.subjectNatural killers
dc.subjectAntibodies
dc.subjectCovid-19
dc.subjectGraft rejection
dc.subjectHumans
dc.subjectKidney transplantation
dc.subjectMale
dc.subjectMiddle aged
dc.subjectTime factors
dc.subjectAntibody
dc.subjectBasiliximab
dc.subjectCd20 antigen
dc.subjectCd3 antigen
dc.subjectComplement component c1q
dc.subjectComplement component c3
dc.subjectCreatinine
dc.subjectDonor specific antibody
dc.subjectHla antigen class 1
dc.subjectHla c antigen
dc.subjectHla cw17 antigen
dc.subjectImmunoglobulin
dc.subjectImmunoglobulin m
dc.subjectMycophenolate mofetil
dc.subjectParacetamol
dc.subjectSteroid
dc.subjectTacrolimus
dc.subjectUnclassified drug
dc.subjectAdult
dc.subjectAntibody dependent cellular cytotoxicity
dc.subjectArticle
dc.subjectClinical article
dc.subjectComplement deposition
dc.subjectComputer assisted tomography
dc.subjectCoronavirus disease 2019
dc.subjectCreatinine blood level
dc.subjectDrug dose reduction
dc.subjectFamily history
dc.subjectFatigue
dc.subjectFever
dc.subjectFocal glomerulosclerosis
dc.subjectGround glass opacity
dc.subjectHemodialysis
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectImmunoglobulin deposition
dc.subjectImmunohistochemistry
dc.subjectKidney biopsy
dc.subjectKidney graft rejection
dc.subjectLiving donor
dc.subjectLow drug dose
dc.subjectLow risk patient
dc.subjectMinimum plasma concentration
dc.subjectNatural killer cell
dc.subjectPlasma exchange
dc.subjectComplication
dc.subjectImmunology
dc.subjectTime factor
dc.titleLate antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1355.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format